LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Stock List・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Closed

SectorHealthcare

64.67 -3.03

Buy Sell

Overview

Share price change

24h

Current

Min

63.67

Max

67.39

Key metrics
By Trading Economics
Income	-7.5M -190M
Sales	33M 154M
Profit margin	-123.403
Employees	834
EBITDA	-6.9M -180M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+58.35% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	361M 13B
Previous open	67.7
Previous close	64.67

News Sentiment

By Acuity

50%

153 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.71 / 36.9 Support & Resistance

Bridgebio Pharma Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 May 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 May 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 May 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 May 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 May 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 May 2026, 10:21 UTC

Earnings

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 May 2026, 06:05 UTC

Earnings

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 May 2026, 23:55 UTC

Earnings

Review & Preview: Still Going Strong -- Barrons.com

8 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 20:49 UTC

Earnings

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 May 2026, 20:25 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 May 2026, 19:43 UTC

Earnings

Cencosud 1Q Net $115M

8 May 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 May 2026, 19:18 UTC

Earnings

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 May 2026, 19:16 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:08 UTC

Earnings

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 May 2026, 19:05 UTC

Earnings

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 May 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 May 2026, 18:51 UTC

Earnings

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 May 2026, 18:49 UTC

Earnings

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 May 2026, 18:41 UTC

Earnings

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 May 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 May 2026, 17:14 UTC

Earnings

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 May 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Bridgebio Pharma Inc Forecast

Price Target

By TipRanks

58.35% upside

12 Months Forecast

Average 106.71 USD 58.35%

High 157 USD

Low 81 USD

Based on 18 Wall Street analysts offering 12 month price targets forBridgebio Pharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Bridgebio Pharma Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.71 / 36.9Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

153 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.